Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s plans for its innovative cancer therapies PTX-100 and PTX-200.
Prescient launched an $8 million capital raising last month to fund the progression of the two therapies towards first in-human clinical studies.
The company is also advancing its next generation OmniCAR CAR-T platform for fighting cancer, which it says can do what conventional CAR-T cannot.
Articles:https://smallcaps.com.au/prescient-therapeutics-enters-strategic-collaboration-renowned-cancer-centre-us/https://smallcaps.com.au/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise/https://smallcaps.com.au/prescient-therapeutics-signs-deal-q-gen-omnicar-clinical-trials/
For more information on Prescient Therapeutics : https://smallcaps.com.au/stocks/PTX/
See omnystudio.com/listener for privacy information.
.png)
More
Religion & Spirituality
Education
Arts and Design
Health
Fashion & Beauty
Government & Organizations
Kids & family
Music
News & Politics
Science & Medicine
Society & Culture
Sports & Recreation
TV & Film
Technology
Philosophy
Storytelling
Horror and Paranomal
True Crime
Leisure
Travel
Fiction
Crypto
Marketing
History
Comedy
Arts
Games & Hobbies
Business
Motivation